Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600txm

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 16:04:58 ON 20 MAY 2007
FILE 'CAPLUS' ENTERED AT 16:04:58 ON 20 MAY 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	65.59	238.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.36	-9.36

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	65.59	238.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.36	-9.36

FILE 'CAPLUS' ENTERED AT 16:05:06 ON 20 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 20 May 2007 VOL 146 ISS 22
FILE LAST UPDATED: 18 May 2007 (20070518/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s us 20070087960/pn
L5 2 US 20070087960/PN
(US2007087960/PN)

=> sel rn
E1 THROUGH E88 ASSIGNED

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.64	240.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-9.36

FILE 'REGISTRY' ENTERED AT 16:05:45 ON 20 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

McIntosh

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 MAY 2007 HIGHEST RN 935394-90-4
DICTIONARY FILE UPDATES: 18 MAY 2007 HIGHEST RN 935394-90-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> s e1-e88
             1 13734-41-3/BI
               (13734-41-3/RN)
             1 20724-73-6/BI
               (20724-73-6/RN)
             1 327614-69-7/BI
               (327614-69-7/RN)
             1 33985-40-9/BI
               (33985-40-9/RN)
             1 4099-85-8/BI
               (4099-85-8/RN)
             1 50-69-1/BI
               (50-69-1/RN)
             1 503543-43-9/BI
               (503543-43-9/RN)
             1 503543-44-0/BI
               (503543-44-0/RN)
             1 55797-67-6/BI
               (55797-67-6/RN)
             1 108-24-7/BI
               (108-24-7/RN)
             1 125911-76-4/BI
               (125911-76-4/RN)
             1 125911-78-6/BI
               (125911-78-6/RN)
             1 149885-80-3/BI
               (149885-80-3/RN)
             1 150993-73-0/BI
               (150993-73-0/RN)
             1 152540-75-5/BI
               (152540-75-5/RN)
             1 152540-76-6/BI
               (152540-76-6/RN)
             1 153186-26-6/BI
               (153186-26-6/RN)
             1 153186-32-4/BI
               (153186-32-4/RN)
             1 15397-12-3/BI
               (15397-12-3/RN)
             1 17397-89-6/BI
               (17397-89-6/RN)
             1 185610-53-1/BI
               (185610-53-1/RN)
             1 188413-99-2/BI
               (188413-99-2/RN)
             1 205171-05-7/BI
               (205171-05-7/RN)
             1 2096-10-8/BI
               (2096-10-8/RN)
             1 243664-63-3/BI
               (243664-63-3/RN)
             1 25322-68-3/BI
```

(25322-68-3/RN)
1 30361-17-2/BI
(30361-17-2/RN)
1 30361-19-4/BI
(30361-19-4/RN)
1 31448-54-1/BI
(31448-54-1/RN)
1 327614-68-6/BI
(327614-68-6/RN)
1 327614-72-2/BI
(327614-72-2/RN)
1 36791-04-5/BI
(36791-04-5/RN)
1 37353-41-6/BI
(37353-41-6/RN)
1 374750-28-4/BI
(374750-28-4/RN)
1 374750-30-8/BI
(374750-30-8/RN)
1 374750-32-0/BI
(374750-32-0/RN)
1 386213-38-3/BI
(386213-38-3/RN)
1 40615-36-9/BI
(40615-36-9/RN)
1 433935-36-5/BI
(433935-36-5/RN)
1 443642-29-3/BI
(443642-29-3/RN)
1 472960-22-8/BI
(472960-22-8/RN)
1 492-30-8/BI
(492-30-8/RN)
1 503543-45-1/BI
(503543-45-1/RN)
1 503543-46-2/BI
(503543-46-2/RN)
1 503543-47-3/BI
(503543-47-3/RN)
1 503543-48-4/BI
(503543-48-4/RN)
1 503543-49-5/BI
(503543-49-5/RN)
1 503543-50-8/BI
(503543-50-8/RN)
1 503543-51-9/BI
(503543-51-9/RN)
1 503543-52-0/BI
(503543-52-0/RN)
1 503543-55-3/BI
(503543-55-3/RN)
1 503806-04-0/BI
(503806-04-0/RN)
1 504-78-9/BI
(504-78-9/RN)
1 565450-78-4/BI
(565450-78-4/RN)
1 57-48-7/BI
(57-48-7/RN)
1 58-96-8/BI
(58-96-8/RN)
1 622381-09-3/BI
(622381-09-3/RN)
1 640281-90-9/BI
(640281-90-9/RN)
1 640281-91-0/BI
(640281-91-0/RN)
1 640725-69-5/BI
(640725-69-5/RN)
1 640725-70-8/BI
(640725-70-8/RN)
1 640725-71-9/BI
(640725-71-9/RN)
1 640725-72-0/BI
(640725-72-0/RN)

```
             1 640725-73-1/BI
               (640725-73-1/RN)
             1 640725-74-2/BI
               (640725-74-2/RN)
             1 640725-75-3/BI
               (640725-75-3/RN)
             1 640725-76-4/BI
               (640725-76-4/RN)
             1 640725-77-5/BI
               (640725-77-5/RN)
             1 645004-11-1/BI
               (645004-11-1/RN)
             1 645004-12-2/BI
               (645004-12-2/RN)
             1 645004-13-3/BI
               (645004-13-3/RN)
             1 645004-14-4/BI
               (645004-14-4/RN)
             1 645004-15-5/BI
               (645004-15-5/RN)
             1 645004-16-6/BI
               (645004-16-6/RN)
             1 65-46-3/BI
               (65-46-3/RN)
             1 65-71-4/BI
               (65-71-4/RN)
             1 66-22-8/BI
               (66-22-8/RN)
             1 67-99-2/BI
               (67-99-2/RN)
             1 71-30-7/BI
               (71-30-7/RN)
             1 7392-74-7/BI
               (7392-74-7/RN)
             1 77-76-9/BI
               (77-76-9/RN)
             1 84-11-7/BI
               (84-11-7/RN)
             1 9012-90-2/BI
               (9012-90-2/RN)
             1 9026-28-2/BI
               (9026-28-2/RN)
             1 93-98-1/BI
               (93-98-1/RN)
             1 951-77-9/BI
               (951-77-9/RN)
             1 98-88-4/BI
               (98-88-4/RN)
             1 98530-12-2/BI
               (98530-12-2/RN)
L6          88 (13734-41-3/BI OR 20724-73-6/BI OR 327614-69-7/BI OR 33985-40-9/
               BI OR 4099-85-8/BI OR 50-69-1/BI OR 503543-43-9/BI OR 503543-44-
               0/BI OR 55797-67-6/BI OR 108-24-7/BI OR 125911-76-4/BI OR 125911-
               78-6/BI OR 149885-80-3/BI OR 150993-73-0/BI OR 152540-75-5/BI OR
               152540-76-6/BI OR 153186-26-6/BI OR 153186-32-4/BI OR 15397-12-3/
               BI OR 17397-89-6/BI OR 185610-53-1/BI OR 188413-99-2/BI OR 205171
               -05-7/BI OR 2096-10-8/BI OR 243664-63-3/BI OR 25322-68-3/BI OR
               30361-17-2/BI OR 30361-19-4/BI OR 31448-54-1/BI OR 327614-68-6/BI
                OR 327614-72-2/BI OR 36791-04-5/BI OR 37353-41-6/BI OR 374750-28
               -4/BI OR 374750-30-8/BI OR 374750-32-0/BI OR 386213-38-3/BI OR
               40615-36-9/BI OR 433935-36-5/BI OR 443642-29-3/BI OR 472960-22-8/
               BI OR 492-30-8/BI OR 503543-45-1/BI OR 503543-46-2/BI OR 503543-4
               7-3/BI OR 503543-48-4/BI OR 503543-49-5/BI OR 503543-50-8/BI OR
               503543-51-9/BI OR 503543-52-0/BI OR 503543-55-3/BI OR 503806-04-0
               /BI OR 504-78-9/BI OR 565450-78-4/BI OR 57-48-7/BI OR 58-96-8/BI
               OR 622381-09-3/BI OR

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               0.45     241.44

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00      -9.36
```

FILE 'CAPLUS' ENTERED AT 16:06:09 ON 20 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 May 2007 VOL 146 ISS 22
FILE LAST UPDATED: 18 May 2007 (20070518/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l6
L7 236284 L6

=> s l5 and l7
L8 2 L5 AND L7

=> d bib abs hitstr 1-2 l8

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:20697 CAPLUS
DN 140:87662
TI 2'- and 3'-nucleoside prodrugs for treating Flaviviridae infections
IN Sommadossi, Jean-pierre; La Colla, Paolo; Storer, Richard; Gosselin, Gilles
PA Idenix (Cayman) Limited, Cayman I.; Centre National de la Recherche Scientifique; Universita Degli Studi di Cagliari
SO PCT Int. Appl., 2498 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2004003000	A2	20040108	WO 2003-IB3901	20030627	
	WO 2004003000	A3	20041104			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	CA 2490200	A1	20040108	CA 2003-2490200	20030627	
	AU 2003263412	A1	20040119	AU 2003-263412	20030627	
	EP 1525209	A2	20050427	EP 2003-761749	20030627	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
	CN 1678621	A	20051005	CN 2003-820690	20030627	
	JP 2005537242	T	20051208	JP 2004-517162	20030627	
	CN 1761677	A	20060419	CN 2003-820501	20030627	
	US 2007087960	A1	20070419	US 2003-608907	20030627	<--
	WO 2005020884	A2	20050310	WO 2004-US15395	20040514	
	WO 2005020884	A3	20060622			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,					

	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
	SN, TD, TG				
	EP 1656093	A2	20060517	EP 2004-776022	20040514
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	US 2007027065	A1	20070201	US 2004-5468	20041206
	US 2007027104	A1	20070201	US 2004-5469	20041206
	US 2007027066	A1	20070201	US 2004-5470	20041206
	US 2007032449	A1	20070208	US 2004-5441	20041206
	US 2007032407	A1	20070208	US 2004-5473	20041206
	US 7192936	B2	20070320		
	US 2007037735	A1	20070215	US 2004-5442	20041206
	US 2007042939	A1	20070222	US 2004-5445	20041206
	US 2007042991	A1	20070222	US 2004-5447	20041206
	US 2007042940	A1	20070222	US 2004-5467	20041206
	US 2007042990	A1	20070222	US 2004-5471	20041206
	US 2007060503	A1	20070315	US 2004-5440	20041206
	US 2007060498	A1	20070315	US 2004-5444	20041206
	US 2007060504	A1	20070315	US 2004-5446	20041206
	US 2007060541	A1	20070315	US 2004-5466	20041206
	US 2007060505	A1	20070315	US 2004-5472	20041206
	NO 2005000466	A	20050323	NO 2005-466	20050127
	IN 2005DN00341	A	20070202	IN 2005-DN341	20050128
PRAI	US 2002-392350P	P	20020628		
	US 2002-392351P	P	20020628		
	US 2003-466194P	P	20030428		
	US 2003-470949P	P	20030514		
	US 2003-608907	A1	20030627		
	US 2003-609298	A1	20030627		
	WO 2003-IB3901	W	20030627		
	WO 2004-US15395	W	20040514		

OS MARPAT 140:87662

AB 2' And 3'-Prodrugs of 1'-, 2'-, 3'-, or 4'-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivs., are described which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C virus and viruses generally that replicate through an RNA-dependent RNA reverse transcriptase. Compds., compns., methods and uses are provided for the treatment of Flaviviridae infection, including HCV infection, that include the administration of an effective amount of the prodrugs of the invention, or their pharmaceutically acceptable salts or derivs. These drugs may optionally be administered in combination or alternation with further antiviral agents to prevent or treat Flaviviridae infections and other related conditions. Preparation of compds. of the invention is included.

IT 9026-28-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NS5B; nucleoside prodrugs for treating Flaviviridae infections)

RN 9026-28-2 CAPLUS

CN Nucleotidyltransferase, ribonucleate, RNA-dependent (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 33985-40-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(de prodrugs for treating Flaviviridae infections)

RN 33985-40-9 CAPLUS

CN β-D-ribo-Pentodialdo-1,4-furanoside, methyl 2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 37353-41-6, Cysteine protease 149885-80-3, NS3 protease
433935-36-5, Polymerase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; nucleoside prodrugs for treating Flaviviridae infections, and use with other agents)
RN 37353-41-6 CAPLUS
CN Proteinase, cysteine (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 149885-80-3 CAPLUS
CN Proteinase, polyprotein-processing, NS3 (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 433935-36-5 CAPLUS
CN Nucleotidyltransferase, polynucleotide (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 20724-73-6P
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(nucleoside prodrugs for treating Flaviviridae infections)
RN 20724-73-6 CAPLUS
CN Cytidine, 2'-C-methyl- (CA INDEX NAME)

Absolute stereochemistry.



IT 125911-78-6 243664-63-3, DNA polymerase β
386213-38-3
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(nucleoside prodrugs for treating Flaviviridae infections)
RN 125911-78-6 CAPLUS
CN 5'-Uridylic acid, 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 243664-63-3 CAPLUS
CN Nucleotidyltransferase, thymine cyclobutane dimer-bypass deoxyribonucleate (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 386213-38-3 CAPLUS
CN 5'-Cytidylic acid, 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 125911-76-4 150993-73-0 640725-72-0
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(nucleoside prodrugs for treating Flaviviridae infections)
RN 125911-76-4 CAPLUS
CN Uridine 5'-(tetrahydrogen triphosphate), 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 150993-73-0 CAPLUS
CN Uridine 5'-(trihydrogen diphosphate), 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 640725-72-0 CAPLUS
CN Cytidine 5'-(trihydrogen diphosphate), 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 374750-28-4
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PKT (Pharmacokinetics); BIOL (Biological study)
(nucleoside prodrugs for treating Flaviviridae infections)
RN 374750-28-4 CAPLUS
CN Cytidine 5'-(tetrahydrogen triphosphate), 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 640725-71-9P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleoside prodrugs for treating Flaviviridae infections)
RN 640725-71-9 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



●2 HCl

IT 2096-10-8 15397-12-3 31448-54-1
188413-99-2 374750-30-8 640725-73-1
640725-74-2 640725-75-3 640725-76-4
640725-77-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleoside prodrugs for treating Flaviviridae infections)
RN 2096-10-8 CAPLUS
CN Adenosine, 2-amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 15397-12-3 CAPLUS
CN Adenosine, 2'-C-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 31448-54-1 CAPLUS
CN Uridine, 2'-C-methyl- (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 188413-99-2 CAPLUS
CN Cytidine, 2'-C-ethynyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 374750-30-8 CAPLUS
CN Guanosine, 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 640725-73-1 CAPLUS
CN Adenosine, 2-amino-2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 640725-74-2 CAPLUS
CN 9H-Purin-2-amine, 6-chloro-9-(2-C-methyl-β-D-ribofuranosyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 640725-75-3 CAPLUS
CN L-Valine, 3',5'-diester with 6-chloro-9-(2-C-methyl-β-D-ribofuranosyl)-9H-purin-2-amine, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 640725-76-4 CAPLUS
CN Adenosine, 2'-C-ethynyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 640725-77-5 CAPLUS
CN Adenosine, 2-amino-N-cyclopropyl-2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 50-69-1, D-Ribose 57-48-7, D-Fructose, reactions
65-71-4, Thymine 66-22-8, Uracil, reactions
71-30-7, Cytosine 77-76-9, 2,2-Dimethoxypropane
98-88-4, Benzoyl chloride 108-24-7, Acetic anhydride
13734-41-3 40615-36-9 185610-53-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(nucleoside prodrugs for treating Flaviviridae infections)
RN 50-69-1 CAPLUS
CN D-Ribose (CA INDEX NAME)

Absolute stereochemistry.



RN 57-48-7 CAPLUS
CN D-Fructose (CA INDEX NAME)

Absolute stereochemistry.



RN 65-71-4 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-methyl- (CA INDEX NAME)



RN 66-22-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione (CA INDEX NAME)



McIntosh

RN 71-30-7 CAPLUS
CN 2(1H)-Pyrimidinone, 6-amino- (CA INDEX NAME)



RN 77-76-9 CAPLUS
CN Propane, 2,2-dimethoxy- (CA INDEX NAME)



RN 98-88-4 CAPLUS
CN Benzoyl chloride (CA INDEX NAME)



RN 108-24-7 CAPLUS
CN Acetic acid, 1,1'-anhydride (CA INDEX NAME)



RN 13734-41-3 CAPLUS
CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 40615-36-9 CAPLUS
CN Benzene, 1,1'-(chlorophenylmethylene)bis[4-methoxy- (CA INDEX NAME)



RN 185610-53-1 CAPLUS
CN Carbamic acid, diphenyl-, 2-[(2-methyl-1-oxopropyl)amino]-1H-purin-6-yl ester (9CI) (CA INDEX NAME)



IT 492-30-8P 4099-85-8P 7392-74-7P
30361-17-2P 30361-19-4P 55797-67-6P
152540-75-5P 327614-69-7P 327614-72-2P
503543-43-9P 503543-44-0P 503543-45-1P
503543-46-2P 503543-47-3P 503543-49-5P
503543-50-8P 503543-51-9P 503543-55-3P
503806-04-0P 640725-69-5P 640725-70-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(nucleoside prodrugs for treating Flaviviridae infections)

RN 492-30-8 CAPLUS
CN D-Ribonic acid, 2-C-methyl-, γ-lactone (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 4099-85-8 CAPLUS
CN β-D-Ribofuranoside, methyl 2,3-O-(1-methylethylidene)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 7392-74-7 CAPLUS
CN D-Ribonic acid, 2-C-methyl-, γ-lactone, 2,3,5-tribenzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 30361-17-2 CAPLUS
CN D-Ribofuranose, 2-C-methyl-, 2,3,5-tribenzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 30361-19-4 CAPLUS
CN D-Ribofuranose, 2-C-methyl-, tetrabenzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 55797-67-6 CAPLUS
CN β-D-erythro-Pentofuranoside, methyl 4-C-(hydroxymethyl)-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 152540-75-5 CAPLUS
CN Uridine, 5-methyl-4'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 327614-69-7 CAPLUS
CN α-L-Lyxofuranoside, methyl 4-C-[(benzoyloxy)methyl]-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 327614-72-2 CAPLUS
CN α-L-Lyxofuranoside, methyl 4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503543-43-9 CAPLUS
CN β-D-Ribofuranoside, methyl 4-C-methyl-2,3-O-(1-methylethylidene)-, benzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503543-44-0 CAPLUS
CN D-Ribofuranose, 4-C-methyl-, 1,2,3-triacetate 5-benzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503543-45-1 CAPLUS
CN Uridine, 4'-C-methyl-, 2',3'-diacetate 5'-benzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503543-46-2 CAPLUS
CN Uridine, 4'-C-methyl-4-thio-, 2',3'-diacetate 5'-benzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503543-47-3 CAPLUS
CN Uridine, 4'-C-methyl-4-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503543-49-5 CAPLUS
CN Uridine, 5-methyl-4'-C-methyl-, 2',3'-diacetate 5'-benzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503543-50-8 CAPLUS
CN Uridine, 5-methyl-4'-C-methyl-, 2',3',5'-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503543-51-9 CAPLUS
CN Uridine, 5-methyl-4'-C-methyl-4-thio-, 2',3',5'-triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503543-55-3 CAPLUS
CN Adenosine, 4'-C-methyl-, 2',3'-diacetate 5'-benzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503806-04-0 CAPLUS
CN Guanosine, 4'-C-methyl-N-(2-methyl-1-oxopropyl)-, 2',3'-diacetate 5'-benzoate 6-(diphenylcarbamate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 640725-69-5 CAPLUS
CN Cytidine, 2'-C-methyl-, 2',3',5'-tribenzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 640725-70-8 CAPLUS
CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-, 3'-ester with 2'-C-methylcytidine (CA INDEX NAME)

Absolute stereochemistry.



IT 152540-76-6P 153186-26-6P 153186-32-4P
503543-48-4P 503543-52-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(nucleoside prodrugs for treating Flaviviridae infections)
RN 152540-76-6 CAPLUS
CN Adenosine, 4'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153186-26-6 CAPLUS
CN Uridine, 4'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153186-32-4 CAPLUS

CN Guanosine, 4'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503543-48-4 CAPLUS
CN Cytidine, 4'-C-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 503543-52-0 CAPLUS
CN Cytidine, 5-methyl-4'-C-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 58-96-8, Uridine 65-46-3, Cytidine 951-77-9,
Deoxycytidine
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(nucleoside prodrugs for treating Flaviviridae infections, and use with other agents)
RN 58-96-8 CAPLUS
CN Uridine (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 65-46-3 CAPLUS
CN Cytidine (CA INDEX NAME)

Absolute stereochemistry.



RN 951-77-9 CAPLUS
CN Cytidine, 2'-deoxy- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 67-99-2, Gliotoxin 84-11-7D, Phenanthrenequinone, derivs. 93-98-1D, Benzanilide, derivs. 504-78-9D, Thiazolidine, derivs. 17397-89-6, Cerulenin 25322-68-3D, Polyethylene glycol, conjugates with interferon α2a 36791-04-5, Ribavirin 98530-12-2, IntronA 205171-05-7 374750-32-0 443642-29-3 472960-22-8, Albuferon 565450-78-4 622381-09-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleoside prodrugs for treating Flaviviridae infections, and use with other agents)
RN 67-99-2 CAPLUS
CN 10H-3,10a-Epidithiopyrazino[1,2-a]indole-1,4-dione, 2,3,5a,6-tetrahydro-6-hydroxy-3-(hydroxymethyl)-2-methyl-, (3R,5aS,6S,10aR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 84-11-7 CAPLUS
CN 9,10-Phenanthrenedione (CA INDEX NAME)



RN 93-98-1 CAPLUS
CN Benzamide, N-phenyl- (CA INDEX NAME)



RN 504-78-9 CAPLUS
CN Thiazolidine (CA INDEX NAME)

RN 17397-89-6 CAPLUS
CN 2-Oxiranecarboxamide, 3-[(4E,7E)-1-oxo-4,7-nonadien-1-yl]-, (2R,3S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 25322-68-3 CAPLUS
CN Poly(oxy-1,2-ethanediyl), α-hydro-ω-hydroxy- (CA INDEX NAME)



RN 36791-04-5 CAPLUS
CN 1H-1,2,4-Triazole-3-carboxamide, 1-β-D-ribofuranosyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 98530-12-2 CAPLUS
CN Interferon α2 (human leukocyte clone pM21 protein moiety reduced) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 205171-05-7 CAPLUS

CN 9H-Purine, 6-chloro-9-(2-C-methyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 374750-32-0 CAPLUS
CN Inosine, 2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 443642-29-3 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-β-D-ribofuranosyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 472960-22-8 CAPLUS
CN Serum albumin (human) fusion protein with interferon α2 (human) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 565450-78-4 CAPLUS
CN Inosine, 2'-C-methyl-6-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 622381-09-3 CAPLUS
CN Cytidine, N-cyclopropyl-2'-C-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 645004-11-1 645004-12-2 645004-13-3
645004-14-4 645004-15-5 645004-16-6
RL: PRP (Properties)
(unclaimed sequence; 2'- and 3'-nucleoside prodrugs for treating Flaviviridae infections)
RN 645004-11-1 CAPLUS
CN RNA, (C-A-U-A-U-G-C-U-C-U-U-A-A-U-C-U-U-U-U-C-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 645004-12-2 CAPLUS
CN RNA, (C-A-U-A-U-G-G-U-C-U-U-A-A-U-C-U-U-U-U-C-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 645004-13-3 CAPLUS
CN RNA, (C-A-U-A-U-G-C-U-G-U-U-A-A-U-C-U-U-U-U-C-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 645004-14-4 CAPLUS
CN RNA, (C-A-U-A-U-C-G-U-C-U-U-A-A-U-C-U-U-U-U-C-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 645004-15-5 CAPLUS
CN RNA, (C-A-U-A-U-C-C-U-G-U-U-A-A-U-C-U-U-U-U-C-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 645004-16-6 CAPLUS
CN RNA, (C-A-U-A-U-C-C-U-C-U-U-A-A-U-G-U-U-U-U-C-C) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 9012-90-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α and γ; nucleoside prodrugs for treating Flaviviridae infections)
RN 9012-90-2 CAPLUS
CN Nucleotidyltransferase, deoxyribonucleate (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:20696 CAPLUS
DN 140:77365
TI Preparation of modified 2'- and 3'-nucleoside prodrugs for treating Flaviviridae infections
IN Sommadossi, Jean-pierre; La Colla, Poalo; Storer, Richard; Gosselin, Gilles

PA Idenix (Cayman) Limited, Cayman I.; Universita degli studi di Cagliari; Centre National de la Recherche Scientifique
SO PCT Int. Appl., 201 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004002999	A2	20040108	WO 2003-IB3246	20030627
	WO 2004002999	A3	20040812		
	WO 2004002999	A8	20050217		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2490191	A1	20040108	CA 2003-2490191	20030627
	AU 2003247084	A1	20040119	AU 2003-247084	20030627
	EP 1523489	A2	20050420	EP 2003-761744	20030627
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1678621	A	20051005	CN 2003-820690	20030627
	JP 2005533817	T	20051110	JP 2004-517158	20030627
	CN 1761677	A	20060419	CN 2003-820501	20030627
	US 2007087960	A1	20070419	US 2003-608907	20030627 <--
	WO 2005020884	A2	20050310	WO 2004-US15395	20040514
	WO 2005020884	A3	20060622		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1656093	A2	20060517	EP 2004-776022	20040514
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	US 2007027065	A1	20070201	US 2004-5468	20041206
	US 2007027104	A1	20070201	US 2004-5469	20041206
	US 2007027066	A1	20070201	US 2004-5470	20041206
	US 2007032449	A1	20070208	US 2004-5441	20041206
	US 2007032407	A1	20070208	US 2004-5473	20041206
	US 7192936	B2	20070320		
	US 2007037735	A1	20070215	US 2004-5442	20041206
	US 2007042939	A1	20070222	US 2004-5445	20041206
	US 2007042991	A1	20070222	US 2004-5447	20041206
	US 2007042940	A1	20070222	US 2004-5467	20041206
	US 2007042990	A1	20070222	US 2004-5471	20041206
	US 2007060503	A1	20070315	US 2004-5440	20041206
	US 2007060498	A1	20070315	US 2004-5444	20041206
	US 2007060504	A1	20070315	US 2004-5446	20041206
	US 2007060541	A1	20070315	US 2004-5466	20041206
	US 2007060505	A1	20070315	US 2004-5472	20041206
	NO 2005000465	A	20050127	NO 2005-465	20050127
PRAI	US 2002-392350P	P	20020628		
	US 2002-392351P	P	20020628		
	US 2003-466194P	P	20030428		
	US 2003-470949P	P	20030514		
	US 2003-608907	A1	20030627		
	US 2003-609298	A1	20030627		
	WO 2003-IB3246	W	20030627		
	WO 2004-US15395	W	20040514		

OS MARPAT 140:77365
GI



I

AB 2' And/or 3' prodrugs of 1', 2', 3' or 4'-branched-nucleosides I, wherein R1-R3 are independently H, phosphate, alkyl, acyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonate ester, benzyl, wherein the Ph group is optionally substituted with one or more substituents, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, lipid, amino acid, carbohydrate, peptide, cholesterol; Y1 is hydrogen, bromo, chloro, fluoro, iodo, CN, OH, OR4, NH2, NHR4, NR4R5, SH or SR4; X1 and X2 are independently alkyl, CH3, CF3, CY3, 2-Br-Et, CH2F, CH2Cl, CH2CF3, CF2CF3, CY2CY3, CH2OH, alkenyl, alkynyl, COOH, COOR4, COO-alkyl, COO-aryl, CO-O-alkoxyalkyl, CONH2, CONHR4, CON(R4)2, halo, CN, N3, OH, OR4, NH2, NHR4, NR4R5, SH or SR5; Y is independently H, halo; and each R4 and R5 is independently hydrogen, acyl, alkyl, lower alkyl, alkenyl, alkynyl or cycloalkyl, and their pharmaceutically acceptable salts and derivs. are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compds. and compns. of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivs. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions. Thus, antiviral activity of β-D-2'-C-methyl-7-methyl-6-phenyl-3,3a,5,8a-tetrahydro-1,3,4,5,7a-penta-aza-s-indacen-8-one is reported.

IT 4099-85-8P 33985-40-9P 55797-67-6P
327614-68-6P 327614-69-7P 503543-43-9P
503543-44-0P 640281-90-9P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of modified and nucleoside prodrugs for treating flaviviridae infections)

RN 4099-85-8 CAPLUS

CN β-D-Ribofuranoside, methyl 2,3-O-(1-methylethylidene)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 33985-40-9 CAPLUS

CN β-D-ribo-Pentodialdo-1,4-furanoside, methyl 2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 55797-67-6 CAPLUS
CN β-D-erythro-Pentofuranoside, methyl 4-C-(hydroxymethyl)-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 327614-68-6 CAPLUS
CN α-L-Lyxofuranoside, methyl 5-O-[bis(4-methoxyphenyl)phenylmethyl]-4-C-(hydroxymethyl)-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 327614-69-7 CAPLUS
CN α-L-Lyxofuranoside, methyl 4-C-[(benzoyloxy)methyl]-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503543-43-9 CAPLUS
CN β-D-Ribofuranoside, methyl 4-C-methyl-2,3-O-(1-methylethylidene)-, benzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503543-44-0 CAPLUS
CN D-Ribofuranose, 4-C-methyl-, 1,2,3-triacetate 5-benzoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 640281-90-9 CAPLUS
CN L-Valine, 3'-ester with 2'-C-methylcytidine (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 640281-91-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of modified and nucleoside prodrugs for treating flaviviridae infections)
RN 640281-91-0 CAPLUS
CN 9H-Imidazo[1,2-a]purin-9-one, 3,4-dihydro-7-methyl-3-(2-C-methyl-β-D-ribofuranosyl)-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 50-69-1, D-Ribose 13734-41-3 20724-73-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of modified and nucleoside prodrugs for treating flaviviridae infections)
RN 50-69-1 CAPLUS
CN D-Ribose (CA INDEX NAME)

Absolute stereochemistry.



RN 13734-41-3 CAPLUS
CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 20724-73-6 CAPLUS
CN Cytidine, 2'-C-methyl- (CA INDEX NAME)

Absolute stereochemistry.



C:\Program Files\Stnexp\Queries\10608907a.str





chain nodes :
7 8 9 10 11 12 14 15
ring nodes :
1 2 3 4 5 6
chain bonds :
1-7 1-11 2-8 2-10 4-6 4-14 5-12 5-15 8-9
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 1-7 2-3 3-4 4-5 4-6 5-12
exact bonds :
1-11 2-8 2-10 4-14 5-15 8-9

G1:H,F

G2:CF3,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 14:CLASS
15:CLASS

```
     (FILE 'HOME' ENTERED AT 14:11:26 ON 20 MAY 2007)

     FILE 'REGISTRY' ENTERED AT 14:11:53 ON 20 MAY 2007
L1                STRUCTURE UPLOADED
L2              3 S L1 SSS SAM
L3            150 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 14:13:03 ON 20 MAY 2007
L4             12 S L3
```

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600txm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 7	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 8	JAN 29	PHAR reloaded with new search and display fields
NEWS 9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13	FEB 26	MEDLINE reloaded with enhancements
NEWS 14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19	MAR 16	CASREACT coverage extended
NEWS 20	MAR 20	MARPAT now updated daily
NEWS 21	MAR 22	LWPI reloaded
NEWS 22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 26	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 28	MAY 01	New CAS web site launched
NEWS 29	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 30	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS EXPRESS		NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS LOGIN		Welcome Banner and News Items
NEWS IPC8		For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:11:26 ON 20 MAY 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

McIntosh

10/608,907

FILE 'REGISTRY' ENTERED AT 14:11:53 ON 20 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 MAY 2007 HIGHEST RN 935394-90-4
DICTIONARY FILE UPDATES: 18 MAY 2007 HIGHEST RN 935394-90-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10608907a.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,F
G2 CF3,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:12:24 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 9556 TO ITERATE

20.9% PROCESSED 2000 ITERATIONS 3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 185261 TO 196979
PROJECTED ANSWERS: 59 TO 513

L2 3 SEA SSS SAM L1

=> d scan

L2 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

McIntosh

IN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, phenylmethyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI)
MF C30 H31 F N5 O7 P

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 9H-Purin-2-amine, 6-chloro-9-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]- (9CI)
MF C11 H13 Cl F N5 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetamide, N-[7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-ethenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI)
MF C16 H19 Cl N4 O4

Absolute stereochemistry.



McIntosh

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 full
FULL SEARCH INITIATED 14:12:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 194430 TO ITERATE

100.0% PROCESSED 194430 ITERATIONS 150 ANSWERS
SEARCH TIME: 00.00.04

L3 150 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.55 172.76

FILE 'CAPLUS' ENTERED AT 14:13:03 ON 20 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 May 2007 VOL 146 ISS 22
FILE LAST UPDATED: 18 May 2007 (20070518/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 12 L3

=> d bib abs hitstr 1-12 l4

L4 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:147988 CAPLUS
DN 146:397251
TI Mechanism of activation of β-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase
AU Murakami, Eisuke; Bao, Haiying; Ramesh, Mangala; McBrayer, Tamara R.; Whitaker, Tony; Steuer, Holly M. Micolochick; Schinazi, Raymond F.; Stuyver, Lieven J.; Obikhod, Aleksandr; Otto, Michael J.; Furman, Phillip A.
CS Pharmasset, Inc., Princeton, NJ, 08540, USA
SO Antimicrobial Agents and Chemotherapy (2007), 51(2), 503-509
CODEN: AMACCQ; ISSN: 0066-4804
PB American Society for Microbiology
DT Journal
LA English
AB β-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) is a potent specific inhibitor of hepatitis C virus (HCV) RNA synthesis in Huh-7 replicon cells. To inhibit the HCV NS5B RNA polymerase, PSI-6130 must be phosphorylated to the 5'-triphosphate form. The phosphorylation of PSI-6130 and inhibition of HCV NS5B were investigated. The phosphorylation of PSI-6130 by recombinant human 2'-deoxycytidine kinase (dCK) and uridine-cytidine kinase 1 (UCK-1) was measured by using a coupled spectrophotometric reaction. PSI-6130 was shown to be a substrate for purified dCK, with a Knt of 81 μM and a kcat of 0.007 s-1, but was not a substrate for UCK-1. PSI-6130 monophosphate (PSI-6130-MP) was

efficiently phosphorylated to the diphosphate and subsequently to the triphosphate by recombinant human UMP-CMP kinase and nucleoside diphosphate kinase, resp. The inhibition of wild-type and mutated (S282T) HCV NS5B RNA polymerases was studied. The steady-state inhibition constant (Ki) for PSI-6130 triphosphate (PSI-6130-TP) with the wild-type enzyme was 4.3 μM. Similar results were obtained with 2'-C-methyladenosine triphosphate (Ki = 1.5 μM) and 2'-C-methylcytidine triphosphate (Ki = 1.6 μM). NS5B with the S282T mutation, which is known to confer resistance to 2'-C-methyladenosine, was inhibited by PSI-6130-TP as efficiently as the wild-type. Incorporation of PSI-6130-MP into RNA catalyzed by purified NS5B RNA polymerase resulted in chain termination.

IT 817204-44-7, PSI 6130 triphosphate 932721-63-6, PSI 6130 monophosphate 932721-64-7, PSI 6130 diphosphate
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(formation; mechanism of activation of β-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase)

RN 817204-44-7 CAPLUS
CN Cytidine 5'-(tetrahydrogen triphosphate), 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 932721-63-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 932721-64-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



IT 817204-33-4, PSI 6130
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(mechanism of activation of β-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase)

RN 817204-33-4 CAPLUS
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1158278 CAPLUS
DN 145:489507
TI Preparation of fluorinated nucleosides for treating hepatitis C
IN Chang, Junbiao; Yu, Xuejun; Bao, Xinhong; Ye, Zhaoting
PA Henan Kaite Chemical Industry General Corporation, Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 12pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1712409	A	20051228	CN 2005-10017709	20050620
PRAI	CN 2005-10017709		20050620		

OS CASREACT 145:489507
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title fluorinated nucleosides I and II [wherein R1 = H, Me, CN, N3, etc.; R2 = H, NH2, OMe, F, Cl, etc.; R3 = H, NH2, F, Cl, etc.; R4 = F, Cl, Br, CN, N3, etc.], or prodrugs or salts thereof were prepared for the treatment of hepatitis C (no data). For example, I [wherein R1 and R3 = H; R2 = 3-thiophenyl] were prepared in a multi-step synthesis.

IT 892389-10-5P 914377-14-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of fluorinated nucleosides for treating hepatitis C)

RN 892389-10-5 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 914377-14-3 CAPLUS
CN 9H-Purine, 9-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-6-(3-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 914377-15-4P 914377-17-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of fluorinated nucleosides for treating hepatitis C)
RN 914377-15-4 CAPLUS
CN 9H-Purine, 9-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-6-(3-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 914377-17-6 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 914377-16-5P 914377-18-7P
RL: BYP (Byproduct); SPN (Synthetic preparation); PREP (Preparation)
(preparation of fluorinated nucleosides for treating hepatitis C)
RN 914377-16-5 CAPLUS
CN 9H-Purine, 9-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-methyl-α-D-erythro-pentofuranosyl]-6-(3-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 914377-18-7 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-methyl-α-D-erythro-pentofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1124279 CAPLUS
DN 145:455221
TI Preparation of nucleoside analogs for treating Flaviviridae family viral infections
IN Roberts, Christopher D.; Griffith, Ronald Conrad; Dyatkina, Natalia B.; Prhavc, Marija
PA Genelabs Technologies, Inc., USA
SO U.S. Pat. Appl. Publ., 71pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2006241064	A1	20061026	US 2006-411434	20060425
WO 2006116557	A1	20061102	WO 2006-US15940	20060425

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-674731P P 20050425
GI

11/44,434

McIntosh



I



II

AB Nucleoside analogs I, wherein Y is O or CH2; X is a halo, hydroxy, alkyl group; W is H, alkyl, etc.; R1 is H, hydroxy, acyl, alkyl, alkoxy; T is an (un)substituted alkynyl group; R2 is an H, alkyl, or a pharmaceutically active prodrug group are prepared for treating viral infections caused by a Flaviviridae family virus. Thus, II was prepared and exhibited 95% inhibition at 6 μM in an HCV-NS5b enzyme assay. Further, I were tested for their anti-Hepatitis C activity against HCV polymerase, in replication assays, and in the cloning expression of recombinant HCV-NS5b.

IT 913188-79-1P 913188-91-7P 913188-92-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of nucleoside analogs for treating Flaviviridae family viral infections)

RN 913188-79-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913188-91-7 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-[(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913188-92-8 CAPLUS

CN 2-Propynoic acid, 3-[4-amino-7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-, ethyl ester

. (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 913188-93-9P 913188-94-0P 913188-95-1P
913188-96-2P 913188-97-3P 913188-98-4P
913188-99-5P 913189-00-1P 913189-01-2P
913189-02-3P 913189-03-4P 913189-04-5P
913189-05-6P 913189-06-7P 913189-07-8P
913189-08-9P 913189-09-0P 913189-10-3P
913189-11-4P 913189-12-5P 913189-13-6P
913189-14-7P 913189-15-8P 913189-16-9P
913189-18-1P 913189-19-2P 913189-20-5P
913189-21-6P 913189-23-8P 913189-24-9P
913189-25-0P 913189-26-1P 913189-27-2P
913189-28-3P 913189-29-4P 913189-30-7P
913189-31-8P 913189-32-9P 913189-33-0P
913189-34-1P 913189-35-2P 913189-36-3P
913189-37-4P 913189-38-5P 913189-39-6P
913189-40-9P 913189-41-0P 913189-42-1P
913189-43-2P 913189-44-3P 913189-45-4P
913189-46-5P 913189-47-6P 913189-48-7P
913189-49-8P 913189-50-1P 913189-51-2P
913189-52-3P 913189-53-4P 913189-54-5P
913189-55-6P 913189-56-7P 913189-57-8P
913189-58-9P 913189-59-0P 913189-60-3P
913189-61-4P 913189-62-5P 913189-63-6P
913189-64-7P 913189-65-8P 913189-66-9P
913189-67-0P 913189-68-1P 913189-69-2P
913189-70-5P 913189-71-6P 913189-72-7P
913189-73-8P 913189-74-9P 913189-75-0P
913189-76-1P 913190-13-3P 913190-14-4P
913190-15-5P 913190-16-6P 913190-17-7P
913190-18-8P 913190-19-9P 913190-20-2P
913190-21-3P 913190-22-4P 913190-23-5P
913190-24-6P 913190-25-7P 913190-26-8P
913190-27-9P 913190-28-0P 913190-29-1P
913190-30-4P 913190-31-5P 913190-32-6P
913190-33-7P 913190-34-8P 913190-35-9P
913190-36-0P 913190-37-1P 913190-38-2P
913190-39-3P 913190-40-6P 913190-41-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nucleoside analogs for treating Flaviviridae family viral infections)

RN 913188-93-9 CAPLUS

CN 2-Propynamide, 3-[4-amino-7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913188-94-0 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-5-O-[[[(1S)-2-methoxy-1-methyl-2-oxoethyl]amino]phenoxyphosphinyl]-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913188-95-1 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913188-96-2 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913188-97-3 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-

β-D-erythro-pentofuranosyl]-5-(2-phenylethynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913188-98-4 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913188-99-5 CAPLUS
CN Boronic acid, [4-amino-7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-00-1 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-01-2 CAPLUS
CN Formaldehyde, [4-amino-7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-02-3 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 913189-03-4 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-nitro-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-04-5 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-(phenylethynyl)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-05-6 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-4-(hydroxyamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-06-7 CAPLUS
CN Boronic acid, [7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-4-(hydroxyamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-07-8 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-1,7-dihydro-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh

RN 913189-08-9 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-[(trimethylsilyl)ethynyl]-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-09-0 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethenyl-1,7-dihydro-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-10-3 CAPLUS
CN Formaldehyde, [7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-4-(hydroxyamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-11-4 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-4-(hydroxyamino)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 913189-12-5 CAPLUS
CN Acetamide, N-[7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-nitro-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-13-6 CAPLUS
CN Acetamide, N-[7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-(phenylethynyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-14-7 CAPLUS
CN Acetamide, N-[7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-formyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-15-8 CAPLUS

CN Boronic acid, [4-(acetylamino)-7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-16-9 CAPLUS
CN Acetamide, N-[7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-18-1 CAPLUS
CN Acetamide, N-[7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-[2-(trimethylsilyl)ethynyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-19-2 CAPLUS
CN Acetamide, N-[7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-20-5 CAPLUS
CN Acetamide, N-[7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-(methylenehydrazino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-21-6 CAPLUS
CN Acetamide, N-[7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-[(hydroxyimino)methyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 913189-23-8 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-nitro-, O-ethyloxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-24-9 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-(phenylethynyl)-, O-ethyloxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-25-0 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-4-(ethoxyamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-26-1 CAPLUS
CN Boronic acid, [7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-4-(ethoxyamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-27-2 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-1,7-dihydro-, O-ethyloxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-28-3 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-[2-(trimethylsilyl)ethynyl]-, O-ethyloxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-29-4 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethenyl-1,7-dihydro-, O-ethyloxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-30-7 CAPLUS
CN Formaldehyde, [7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-4-(ethoxyamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-31-8 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-4-(ethoxyamino)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 913189-32-9 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-33-0 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-(phenylethynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-34-1 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-35-2 CAPLUS
CN Boronic acid, [4-amino-7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-36-3 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-37-4 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-[2-(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh

RN 913189-38-5 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-ethenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-39-6 CAPLUS
CN Formaldehyde, [4-amino-7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-40-9 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 913189-41-0 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-nitro-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-42-1 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-(phenylethynyl)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-43-2 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-4-(hydroxyamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-44-3 CAPLUS
CN Boronic acid, [7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-4-(hydroxyamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh

RN 913189-45-4 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-1,7-dihydro-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-46-5 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-[(trimethylsilyl)ethynyl]-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-47-6 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-ethenyl-1,7-dihydro-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-48-7 CAPLUS
CN Formaldehyde, [7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-4-(hydroxyamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-49-8 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-4-(hydroxyamino)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 913189-50-1 CAPLUS
CN Acetamide, N-[7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-nitro-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-51-2 CAPLUS
CN Acetamide, N-[7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-(phenylethynyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh

RN 913189-52-3 CAPLUS
CN Acetamide, N-[7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-formyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-53-4 CAPLUS
CN Boronic acid, [4-(acetylamino)-7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-54-5 CAPLUS
CN Acetamide, N-[7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-55-6 CAPLUS
CN Acetamide, N-[7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-[(trimethylsilyl)ethynyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-56-7 CAPLUS
CN Acetamide, N-[7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-ethenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-57-8 CAPLUS
CN Acetamide, N-[7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-(methylenehydrazino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-58-9 CAPLUS
CN Acetamide, N-[7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-[(hydroxyimino)methyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



McIntosh

RN 913189-59-0 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-nitro-, O-ethyloxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-60-3 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-(phenylethynyl)-, O-ethyloxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-61-4 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-4-(ethoxyamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-62-5 CAPLUS
CN Boronic acid, [7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-4-(ethoxyamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-63-6 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-1,7-dihydro-, O-ethyloxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-64-7 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-1,7-dihydro-5-[(trimethylsilyl)ethynyl]-, O-ethyloxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-65-8 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-ethenyl-1,7-dihydro-, O-ethyloxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-66-9 CAPLUS
CN Formaldehyde, [7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-4-(ethoxyamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-67-0 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 7-[(2R)-2-chloro-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-4-(ethoxyamino)-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 913189-68-1 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-bromo-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-69-2 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-bromo-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-(phenylethynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-70-5 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-[(2R)-2-bromo-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-71-6 CAPLUS
CN Boronic acid, [4-amino-7-[(2R)-2-bromo-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-72-7 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-bromo-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-73-8 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-bromo-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-[(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-74-9 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-bromo-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-5-ethenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-75-0 CAPLUS
CN Formaldehyde, [4-amino-7-[(2R)-2-bromo-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]hydrazone (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913189-76-1 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboxaldehyde, 4-amino-7-[(2R)-2-bromo-2-deoxy-2-methyl-β-D-erythro-pentofuranosyl]-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 913190-13-3 CAPLUS
CN L-Valine, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-14-4 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-5-O-[bis[2-[(2,2-dimethyl-1-oxopropyl)thio]ethoxy]phosphinyl]-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-15-5 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-5-O-[bis[2-[(3-methyl-1-oxobutyl)thio]ethoxy]phosphinyl]-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-16-6 CAPLUS

CN L-Alanine, N-[hydroxy(4-methoxyphenoxy)phosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-17-7 CAPLUS
CN L-Alanine, N-[(4-fluorophenoxy)hydroxyphosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-18-8 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, ethyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-19-9 CAPLUS
CN L-Alanine, N-[hydroxy(4-methylphenoxy)phosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-20-2 CAPLUS
CN L-Alanine, N-[hydroxy(4-propylphenoxy)phosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-21-3 CAPLUS
CN L-Alanine, N-(hydroxyphenoxyphosphinyl)-, phenylmethyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-22-4 CAPLUS
CN L-Alanine, N-[hydroxy(2-naphthalenyloxy)phosphinyl]-, phenylmethyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh

RN 913190-23-5 CAPLUS
CN L-Alanine, N-[hydroxy(1-naphthalenyloxy)phosphinyl]-, phenylmethyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-24-6 CAPLUS
CN L-Alanine, N-[[(4-chloro-1-naphthalenyl)oxy]hydroxyphosphinyl]-, phenylmethyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-25-7 CAPLUS
CN L-Alanine, N-[hydroxy[(4-methoxy-1-naphthalenyl)oxy]phosphinyl]-, phenylmethyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-26-8 CAPLUS
CN L-Phenylalanine, N-(hydroxyphenoxyphosphinyl)-, methyl ester, 5'-ester

with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-27-9 CAPLUS
CN L-Phenylalanine, N-[hydroxy(4-methoxyphenoxy)phosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-28-0 CAPLUS
CN L-Phenylalanine, N-[(4-fluorophenoxy)hydroxyphosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-29-1 CAPLUS
CN L-Phenylalanine, N-[hydroxy(4-methylphenoxy)phosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-30-4 CAPLUS
CN L-Valine, N-(hydroxyphenoxyphosphinyl)-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-31-5 CAPLUS
CN L-Valine, N-[hydroxy(4-methoxyphenoxy)phosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-32-6 CAPLUS
CN L-Valine, N-[(4-fluorophenoxy)hydroxyphosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh

RN 913190-33-7 CAPLUS
CN L-Valine, N-[hydroxy(4-methylphenoxy)phosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-34-8 CAPLUS
CN Alanine, N-(hydroxyphenoxyphosphinyl)-2-methyl-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-35-9 CAPLUS
CN Alanine, N-(hydroxyphenoxyphosphinyl)-2-methyl-, phenylmethyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-36-0 CAPLUS
CN Alanine, N-[(4-fluorophenoxy)hydroxyphosphinyl]-2-methyl-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-37-1 CAPLUS
CN Alanine, N-[hydroxy(4-methoxyphenoxy)phosphinyl]-2-methyl-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-38-2 CAPLUS
CN L-Proline, 1-(hydroxyphenoxyphosphinyl)-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-39-3 CAPLUS
CN L-Proline, 1-(hydroxyphenoxyphosphinyl)-, phenylmethyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh

RN 913190-40-6 CAPLUS
CN L-Proline, 1-[(4-fluorophenoxy)hydroxyphosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913190-41-7 CAPLUS
CN L-Proline, 1-[hydroxy(4-methoxyphenoxy)phosphinyl]-, methyl ester, 5'-ester with 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-ethynyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (CA INDEX NAME)

Absolute stereochemistry.



IT 913188-88-2P 913188-89-3P 913188-90-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of nucleoside analogs for treating Flaviviridae family viral infections)

RN 913188-88-2 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-[(2R)-2-deoxy-2-fluoro-2-methyl-3,5-bis-O-(tetrahydro-2H-pyran-2-yl)-β-D-erythro-pentofuranosyl]-5-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913188-89-3 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913188-90-6 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:985303 CAPLUS
DN 145:505687
TI Synthesis of 2-deoxy-2-fluoro-2-C-methyl-D-ribofuranoses
AU Clark, Jeremy L.; Mason, J. Christian; Hobbs, Ann J.; Hollecker, Laurent; Schinazi, Raymond F.
CS Pharmasset, Inc., Tucker, GA, USA
SO Journal of Carbohydrate Chemistry (2006), 25(6), 461-470
CODEN: JCACDM; ISSN: 0732-8303
PB Taylor & Francis, Inc.
DT Journal
LA English
OS CASREACT 145:505687
AB The synthesis of Me 3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-C-methyl-β-D-ribofuranoside and the conversion to the corresponding 1-O-acetyl-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-C-methyl-D-ribofuranose and 1,3,5-tri-O-benzoyl-2-deoxy-2-fluoro-2-C-methyl-D-ribofuranose is reported. The key synthetic step is the fluorination of the tertiary center of Me 3,5-di-O-benzyl-2-C-methyl-β-D-arabinofuranoside to provide Me 3,5-di-O-benzyl-2-deoxy-2-fluoro-2-C-methyl-β-D-ribofuranoside.
IT 817204-32-3P 874638-94-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of 2-deoxy-2-fluoro-2-C-methyl-D-ribofuranoses via fluorination of the tertiary center of Me 3,5-di-O-benzyl-2-C-methyl-β-D-arabinofuranosides)
RN 817204-32-3 CAPLUS
CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 874638-94-5 CAPLUS
CN Benzamide, N-[1-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-methyl-α-D-erythro-pentofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:603846 CAPLUS
DN 145:76603
TI Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
IN Maccoss, Malcolm; Olsen, David B.; Leone, Joseph; Durette, Philippe L.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006065335	A2	20060622	WO 2005-US37224	20051017
	WO 2006065335	A3	20060914		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-620743P P 20041021
US 2005-651366P P 20050209
OS MARPAT 145:76603
AB The present invention provides fluorinated pyrrolo[2,3, d]pyrimidine nucleoside compds. which are inhibitors of RNA-dependent RNA viral polymerase. These compds. are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of

HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compns. containing such fluorinated pyrrolo[2,3- d]pyrimidine nucleoside alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the fluorinated pyrrolo[2,3- d]pyrimidine nucleoside of the present invention.

IT 892389-29-6 892389-31-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fluorinated pyrrolopyrimidine nucleosides for treatment of RNA-dependent RNA viral infection)

RN 892389-29-6 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 892389-31-0 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-fluoro-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 892389-27-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(fluorinated pyrrolopyrimidine nucleosides for treatment of RNA-dependent RNA viral infection)

RN 892389-27-4 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-7-[(2R)-3,5-di-O-acetyl-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh

IT 892389-10-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(fluorinated pyrrolopyrimidine nucleosides for treatment of RNA-dependent RNA viral infection)
RN 892389-10-5 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:478128 CAPLUS
DN 145:202057
TI Inhibition of hepatitis C replicon RNA synthesis by β-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication
AU Stuyver, Lieven J.; McBrayer, Tamara R.; Tharnish, Phillip M.; Clark, Jeremy; Hollecker, Laurent; Lostia, Stefania; Nachman, Tammy; Grier, Jason; Bennett, Matthew A.; Xie, Meng-Yu; Schinazi, Raymond F.; Morrey, John D.; Julander, Justin L.; Furman, Phillip A.; Otto, Michael J.
CS Pharmasset Inc, Princeton, NJ, USA
SO Antiviral Chemistry & Chemotherapy (2006), 17(2), 79-87
CODEN: ACCHEH; ISSN: 0956-3202
PB International Medical Press, Ltd.
DT Journal
LA English
AB β-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) is a cytidine analog with potent and selective anti-hepatitis C virus (HCV) activity in the subgenomic HCV replicon assay, 90% effective concentration (EC90) = 4.6 ± 2.0 μM. The spectrum of activity and cytotoxicity profile of PSI-6130 was evaluated against a diverse panel of viruses and cell types, and against two addnl. HCV-1b replicons. The S282T mutation, which confers resistance to 2'-C-Me adenosine and other 2'-methylated nucleosides, showed only a 6.5-fold increase in EC90. When assayed for activity against bovine diarrhoea virus (BVDV), which is typically used as a surrogate assay to identify compds. active against HCV, PSI-6130 showed no anti-BVDV activity. Weak antiviral activity was noted against other flaviviruses, including West Nile virus, Dengue type 2, and yellow fever virus. These results indicate that PSI-6130 is a specific inhibitor of HCV. PSI-6130 showed little or no cytotoxicity against various cell types, including human peripheral blood mononuclear and human bone marrow progenitor cells. No mitochondrial toxicity was observed with PSI-6130. The reduced activity against the RdRp S282T mutant suggests that PSI-6130 is an inhibitor of replicon RNA synthesis. Finally, the no-effect dose for mice treated i.p. with PSI-6130 for six consecutive days was ≥100 mg/kg per day.
IT 817204-33-4, PSI 6130
RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PSI-6130 inhibition of hepatitis C replicon RNA synthesis)
RN 817204-33-4 CAPLUS
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:269477 CAPLUS
DN 144:312289
TI Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs via condensation of the lactone to nucleosides as potential antiviral agents
IN Chun, Byoung-Kwon; Wang, Peiyuan
PA Pharmasset, Inc., USA
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006031725	A2	20060323	WO 2005-US32406	20050913
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006122146	A1	20060608	US 2005-225425	20050913
PRAI US 2004-609783P	P	20040914		
US 2004-610035P	P	20040915		
US 2005-666230P	P	20050329		

OS MARPAT 144:312289
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A process for preparing of 2-deoxy-2-fluoro-2-methyl-D-ribonolactones, I, wherein R1 and R2 can independently be H, CH3, acetyl, benzoyl, pivaloyl, 4-nitrobenzoyl, 3-nitrobenzoyl, 2-nitrobenzoyl, 4-chlorobenzoyl, 3-chlorobenzoyl, 2-chlorobenzoyl, 4-methylbenzoyl, 3-methylbenzoyl, 2-methylbenzoyl, 4-phenylbenzoyl, benzyl, 4-methoxybenzyl, trityl, trialkylsilyl, t-butyl-dialkylsilyl, t-butyldiphenylsilyl, TIPDS, THP, MOM, or MEM are prepared and used in the condensation to 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs. Thus, 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs II and III, wherein X is a halogen; Y is N or CH; Z is a halogen, hydroxyl, ether, thiol, thioether, (un)substituted amine or alkyl; R1' is alkyl, vinyl, ethynyl; R2' and R3' can be same or different H, alkyl, arylalkyl, acyl, cyclic acetal such as 2',3'-O-isopropylidene or 2',3-O-benzylidene, or 2',3'-cyclic carbonate; R4, R5, and R6 are independently H, halogen, hydroxyl, ether, thiol, thioether, N3, (un)substituted amine, (un)substituted amido, alkyl, halogenated alkyl, alkenyl, halogenated alkenyl, alkynyl, halogenated alkynyl, hydroxy alkyl, alkoxy are prepared and are potential anti-HCV agents. Specifically, IV was prepared in 88 % yield via condensation, alkylation and stereoselective fluorination reactions and can exhibit potential use as an anti-HCV agent.
IT 879551-07-2P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs via condensation of the lactone to nucleosides)

RN 879551-07-2 CAPLUS
CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-bis(2,2-dimethylpropanoate), (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:128527 CAPLUS
DN 144:370341
TI Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication
AU Clark, Jeremy L.; Mason, J. Christian; Hollecker, Laurent; Stuyver, Lieven J.; Tharnish, Phillip M.; McBrayer, Tamara R.; Otto, Michael J.; Furman, Phillip A.; Schinazi, Raymond F.; Watanabe, Kyoichi A.
CS Pharmasset, Inc., Tucker, GA, 30084, USA
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(6), 1712-1715
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 144:370341
GI



I

AB A series of purine nucleosides, e.g. I, containing the 2'-deoxy-2'-fluoro-2'-C-methylribofuranosyl moiety were synthesized and evaluated as potential inhibitors of the hepatitis C virus in vitro. Of the nucleosides that were synthesized, only those possessing a 2-amino group on the purine base reduced the levels of HCV RNA in a sub-genomic replicon assay.

IT 881881-89-6P
RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and antiviral activity of deoxyfluoromethyl purine nucleosides as inhibitors of hepatitis C virus RNA replication)

RN 881881-89-6 CAPLUS
CN 9H-Purin-2-amine, 6-chloro-9-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 817204-42-5P 817204-45-8P 818374-78-6P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and antiviral activity of deoxyfluoromethyl purine nucleosides as inhibitors of hepatitis C virus RNA replication)
RN 817204-42-5 CAPLUS
CN 9H-Purine, 6-chloro-9-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817204-45-8 CAPLUS
CN Guanosine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 818374-78-6 CAPLUS
CN Adenosine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 817204-41-4P 881881-83-0P 881881-88-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and antiviral activity of deoxyfluoromethyl purine nucleosides as inhibitors of hepatitis C virus RNA replication)
RN 817204-41-4 CAPLUS
CN 9H-Purine, 6-chloro-9-[(2R)-3,5-di-O-acetyl-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 881881-83-0 CAPLUS
CN 9H-Purin-2-amine, 6-chloro-9-[(2R)-3,5-di-O-acetyl-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]-N-(triphenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 881881-88-5 CAPLUS
CN 9H-Purin-2-amine, 6-chloro-9-[(2R)-3,5-di-O-acetyl-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:103884 CAPLUS
DN 144:171198
TI Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs via condensation of the lactone to nucleosides as potential antiviral agents
IN Wang, Peiyuan; Stec, Wojciech; Clark, Jeremy; Chun, Byoung-Kwon; Shi, Junxing; Du, Jinfa
PA Pharmasset, Inc., USA

SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006012440	A2	20060202	WO 2005-US25916	20050721
	WO 2006012440	A3	20060727		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005267051	A1	20060202	AU 2005-267051	20050721
	CA 2574651	A1	20060202	CA 2005-2574651	20050721
	EP 1773856	A2	20070418	EP 2005-775359	20050721
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	US 2006199783	A1	20060907	US 2006-353597	20060213
PRAI	US 2004-589866P	P	20040721		
	US 2004-608320P	P	20040909		
	US 2005-185988	A1	20050721		
	WO 2005-US25916	W	20050721		

OS MARPAT 144:171198
GI

11/353,597

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A process for preparing of 2-deoxy-2-fluoro-2-methyl-D-ribonolactones, I, wherein R1 and R2 can independently be H, CH3, acetyl, benzoyl, pivaloyl, 4-nitrobenzoyl, 3-nitrobenzoyl, 2-nitrobenzoyl, 4-chlorobenzoyl, 3-chlorobenzoyl, 2-chlorobenzoyl, 4-methylbenzoyl, 3-methylbenzoyl, 2-methylbenzoyl, 4-phenylbenzoyl, benzyl, 4-methoxybenzyl, trityl, trialkylsilyl, t-butyl-dialkylsilyl, t-butyldiphenylsilyl, TIPDS, THP, MOM, or MEM are prepared and used in the condensation to 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs. Thus, 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs II and III, wherein X is a halogen; Y is N or CH; Z is a halogen, hydroxyl, ether, thiol, thioether, (un)substituted amine or alkyl; R1' is alkyl, vinyl, ethynyl; R2' and R3' can be same or different H, alkyl, arylalkyl, acyl, cyclic acetal such as 2',3'-O-isopropylidene or 2',3-O-benzylidene, or 2',3'-cyclic carbonate; R4, R5, and R6 are independently H, halogen, hydroxyl, ether, thiol, thioether, N3, (un)substituted amine, (un)substituted amido, alkyl, halogenated alkyl, alkenyl, halogenated alkenyl, alkynyl, halogenated alkynyl, hydroxy alkyl, alkoxy are prepared and are potential anti-HCV agents. Specifically, IV was prepared (no yield, claimed) via condensation, alkylation and stereoselective fluorination reactions and can exhibit potential use as an anti-HCV agent.

IT 874638-97-8P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs via condensation of the lactone to nucleosides)

RN 874638-97-8 CAPLUS
CN Adenosine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 817204-32-3P 817204-33-4P 874638-82-1P
874638-94-5P 874638-95-6P 874638-98-9P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs via condensation of the lactone to nucleosides)

RN 817204-32-3 CAPLUS
CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 817204-33-4 CAPLUS
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 874638-82-1 CAPLUS
CN Benzamide, N-[1-[(2R)-5-O-benzoyl-2-deoxy-2-fluoro-2-methyl-3-O-(methylsulfonyl)-β-D-erythro-pentofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 874638-94-5 CAPLUS
CN Benzamide, N-[1-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-methyl-α-D-erythro-pentofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 874638-95-6 CAPLUS
CN Adenosine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 874638-98-9 CAPLUS
CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:648160 CAPLUS
DN 143:248607
TI Design, Synthesis, and Antiviral Activity of 2'-Deoxy-2'-fluoro-2'-C-methyl-cytidine, a Potent Inhibitor of Hepatitis C Virus Replication
AU Clark, Jeremy L.; Hollecker, Laurent; Mason, J. Christian; Stuyver, Lieven J.; Tharnish, Phillip M.; Lostia, Stefania; McBrayer, Tamara R.; Schinazi, Raymond F.; Watanabe, Kyoichi A.; Otto, Michael J.; Furman, Phillip A.; Stec, Wojciech J.; Patterson, Steven E.; Pankiewicz, Krzysztof W.
CS Pharmasset, Inc., Princeton, NJ, 08540, USA
SO Journal of Medicinal Chemistry (2005), 48(17), 5504-5508
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB The pyrimidine nucleoside- β-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine (I) was designed as a hepatitis C virus RNA-dependent RNA polymerase (HCV RdRp) inhibitor. The title compound was obtained by a DAST fluorination of N4-benzoyl-1-(2-methyl-3,5-di-O-benzoyl-β-D-arabinofuranosyl)cytosine to provide N4-benzoyl-1-(2-fluoro-2-methyl-3,5-di-O-benzoyl-β-D-ribofuranosyl)cytosine. The protected 2'-C-methylcytidine was obtained as a byproduct from the DAST fluorination and allowed for the preparation of two biol. active compds. from a common precursor. Compound I and 2'-C-methylcytidine were assayed in a sub-genomic HCV replicon assay system and found to be potent and selective inhibitors of HCV replication. Compd.I shows increased inhibitory activity in the HCV replicon assay compared to 2'-C-methylcytidine and low cellular toxicity.
IT 817204-33-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(design, synthesis via fluorination, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-cytidine, a potent inhibitor of Hepatitis C virus replication)
RN 817204-33-4 CAPLUS
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 863329-66-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(design, synthesis via fluorination, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-cytidine, a potent inhibitor of Hepatitis C virus replication)
RN 863329-66-2 CAPLUS
CN Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 817204-32-3P 863329-65-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(design, synthesis via fluorination, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-cytidine, a potent inhibitor of Hepatitis C virus replication)

RN 817204-32-3 CAPLUS
CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 863329-65-1 CAPLUS
CN Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 817204-38-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(design, synthesis via fluorination, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-cytidine, a potent inhibitor of Hepatitis C virus replication)

RN 817204-38-9 CAPLUS
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, monohydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:34765 CAPLUS
DN 142:94074

TI Preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-methyl nucleoside analogs as antiviral agents

IN Clark, Jeremy
PA Pharmasset, Ltd., Barbados

SO PCT Int. Appl., 228 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005003147	A2	20050113	WO 2004-US12472	20040421
	WO 2005003147	A3	20050303		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004253860	A2	20050113	AU 2004-253860	20040421
	AU 2004253860	A1	20050113		
	CA 2527657	A1	20050113	CA 2004-2527657	20040421
	US 2005009737	A1	20050113	US 2004-828753	20040421
	EP 1633766	A2	20060315	EP 2004-775900	20040421
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004010846	A	20060627	BR 2004-10846	20040421
	CN 1816558	A	20060809	CN 2004-80019148	20040421
	JP 2006526629	T	20061124	JP 2006-513231	20040421
	NO 2005006221	A	20051228	NO 2005-6221	20051228
PRAI	US 2003-474368P	P	20030530		
	WO 2004-US12472	W	20040421		

OS MARPAT 142:94074

GI



I

AB The disclosed invention provides nucleoside analogs I, wherein B is purine and pyrimidine nucleobase; X is O, S, CH2, Se, NH, N-alkyl, CHW, C(W)2; W is F, Cl, Br, iodo; R1 is H, phosphate, H-phosphonate, acyl, Ph, alkyl, carboxyalkylamino, sulfonate ester, peptide, amino acid, sugar reside; R2 and R2' are independently H, alkyl, alkenyl, alkynyl, vunyl, N3, CN, halogen, NO2, ester, alkoxy, thioalkyl, sulfoxide, sulfonyl; R6 is alkyl, CN, Me, OMe, OEt, CH2OH, CH2F, N3, CHCN, CH2N3, CH2NH2, CH2NHMe, CH2NMe2, alkylne; and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially human, using a (2'R)-2'-deoxy-2'-fluoro-2'-C-Me nucleosides, or a pharmaceutically acceptable salt or prodrug thereof. Thus, (2'R)-2'-deoxy-2'-fluoro-2'-C-methylcytidine was prepared and tested as antiviral agent. The effects the nucleoside analogs tested on human bone marrow cells are reported. (2'R)-2'-deoxy-2'-fluoro-2'-C-methylcytidine shows activity against Rhinovirus, West Nile virus, Yellow Fever virus, and Dengue virus. Cytotoxicity and effect of nucleoside analogs on human bone marrow cells are reported.

IT 817204-33-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-Me nucleoside analogs as antiviral agents)

McIntosh

RN 817204-33-4 CAPLUS
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 817204-38-9P 817204-42-5P 817204-43-6P
817204-45-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-Me nucleoside analogs as antiviral agents)
RN 817204-38-9 CAPLUS
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, monohydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 817204-42-5 CAPLUS
CN 9H-Purine, 6-chloro-9-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817204-43-6 CAPLUS
CN Adenosine, 2'-deoxy-2'-fluoro-2'-methyl-, monohydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 817204-45-8 CAPLUS
CN Guanosine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 817204-44-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-Me nucleoside analogs as antiviral agents)
RN 817204-44-7 CAPLUS
CN Cytidine 5'-(tetrahydrogen triphosphate), 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 817204-32-3P 817204-37-8P 817204-41-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-Me nucleoside analogs as antiviral agents)
RN 817204-32-3 CAPLUS
CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 817204-37-8 CAPLUS
CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-bis(trifluoroacetate), (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817204-41-4 CAPLUS
CN 9H-Purine, 6-chloro-9-[(2R)-3,5-di-O-acetyl-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:114368 CAPLUS
DN 138:304462
TI Synthesis of 2'-C-β-Fluoromethyluridine
AU Dai, Qing; Piccirilli, Joseph A.
CS Howard Hughes Medical Institute, Department of Biochemistry & Molecular Biology, Department of Chemistry, The University of Chicago, Chicago, IL, 60637, USA
SO Organic Letters (2003), 5(6), 807-810
CODEN: ORLEF7; ISSN: 1523-7060
PB American Chemical Society
DT Journal
LA English
OS CASREACT 138:304462
AB 2'-C-β-Fluoromethyluridine represents both a potentially important biol. agent and a tool for biochem. anal. Here the authors describe the first synthesis of this compound starting from uridine. The key steps include protection of the uracil base with methoxyethoxymethyl (MEM) chloride, conversion to the corresponding 2'-C-α-epoxide, and regioselective opening of the oxirane ring with potassium fluoride/hydrogen fluoride. Subsequent acetylation of the 3'- and

5'-hydroxyl groups enables MEM removal using B-bromocatecholborane. Deacetylation generates the parent nucleoside, 2'-C-β-fluoromethyluridine.

IT 510765-38-5P
RL: BYP (Byproduct); PREP (Preparation)
(synthesis of C-β-fluoromethyluridine from uridine via uracil protection with MEM, epoxidn. and regioselective ring opening)

RN 510765-38-5 CAPLUS
CN Uridine, 2'-deoxy-2'-fluoro-2'-(hydroxymethyl)-3-[(2-methoxyethoxy)methyl]-, (2'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:11:26 ON 20 MAY 2007)

FILE 'REGISTRY' ENTERED AT 14:11:53 ON 20 MAY 2007
L1 STRUCTURE UPLOADED
L2 3 S L1 SSS SAM
L3 150 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:13:03 ON 20 MAY 2007
L4 12 S L3